Treatment of chronic hepatitis C infection: one step at a time

被引:8
作者
Davis, GL
Lindsay, KL
机构
[1] Baylor Univ, Med Ctr, Div Hepatol, Dallas, TX 75246 USA
[2] Baylor Reg Transplant Inst, Dallas, TX USA
[3] Univ So Calif, Dept Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA USA
关键词
D O I
10.1016/S1473-3099(05)70193-6
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Non-A, non-B hepatitis was recognised as an important cause of chronic liver disease long before the aetiological agent-hepatitis C virus-was identified in 1989. Recombinant interferons, initially developed as a treatment for Malignancies, proved to be an effective treatment for this disease before the identification. of the viral agent. Subsequent testing for hepatitis C virus RNA demonstrated that the virus appeared to be eradicated in a small proportion of treated patients. Treatment regimens have improved dramatically since 1989 with the addition of the oral nucleoside ribavirin and long-acting pegylated interferons to treatment regimens. Currently, more than half of treated patients can achieve durable viral clearance. This clearance is quite a remarkable feat; indeed, eradication is not possible in any other chronic viral infection. Considerable effort continues to be devoted to improving therapeutic regimens to make them more effective and tolerable. Drugs that directly act on the replicative machinery of the virus-protease and polymerase inhibitors-are under development and entering clinical trials in human beings.
引用
收藏
页码:524 / 526
页数:3
相关论文
共 33 条
  • [1] Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study
    Afdhal, NH
    Dieterich, DT
    Pockros, PJ
    Schiff, ER
    Shiffman, ML
    Sulkowski, MS
    Wright, T
    Younossi, Z
    Goon, BL
    Tang, KL
    Bowers, PJ
    [J]. GASTROENTEROLOGY, 2004, 126 (05) : 1302 - 1311
  • [2] HEPATITIS-C - AND MILES TO GO BEFORE WE SLEEP
    ALTER, MJ
    SAMPLINER, RE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1538 - 1540
  • [3] ARIMA T, 1989, Gastroenterologia Japonica, V24, P545
  • [4] COMPARISON OF 1 OR 3 MU OF INTERFERON ALFA-2B AND PLACEBO IN PATIENTS WITH CHRONIC NON-A, NON-B HEPATITIS
    CAUSSE, X
    GODINOT, H
    CHEVALLIER, M
    CHOSSEGROS, P
    ZOULIM, F
    OUZAN, D
    HEYRAUD, JP
    FONTANGES, T
    ALBRECHT, J
    MESCHIEVITZ, C
    TREPO, C
    [J]. GASTROENTEROLOGY, 1991, 101 (02) : 497 - 502
  • [5] ISOLATION OF A CDNA CLONE DERIVED FROM A BLOOD-BORNE NON-A, NON-B VIRAL-HEPATITIS GENOME
    CHOO, QL
    KUO, G
    WEINER, AJ
    OVERBY, LR
    BRADLEY, DW
    HOUGHTON, M
    [J]. SCIENCE, 1989, 244 (4902) : 359 - 362
  • [6] Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Chung, RT
    Andersen, J
    Volberding, P
    Robbins, GK
    Liu, T
    Sherman, KE
    Peters, MG
    Koziel, MJ
    Bhan, AK
    Alston, B
    Colquhoun, D
    Nevin, T
    Harb, G
    van der Horst, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) : 451 - 459
  • [7] Davis G, 1999, HEPATOLOGY, V30, p303A
  • [8] DAVIS GL, 1984, GASTROENTEROLOGY, V86, P1315
  • [9] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Davis, GL
    Wong, JB
    McHutchison, JG
    Manns, MP
    Harvey, J
    Albrecht, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 645 - 652
  • [10] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506